Table 3 Economic evaluation on immunotherapy combination versus chemotherapy
Cost ($) | Incremental Cost ($) | QALYs | Incremental QALYs | ICER ($/QALY) | |
|---|---|---|---|---|---|
Chemo | 19,505.60 | - | 0.93 | - | - |
Sint-chemo | 35,216.04 | 15,710.44 | 1.38 | 0.45 | 34,912.09 |
Pem-chemo | 102,747.84 | 83,242.24 | 1.35 | 0.42 | 198,195.81 |
Nivo-ipi-chemo | 124,842.78 | 105,337.18 | 1.24 | 0.31 | 339,797.35 |
Tisle-chemo | 37,738.81 | 18,233.21 | 1.28 | 0.35 | 52,094.89 |
Camre-chemo | 32,686.25 | 13,180.65 | 1.22 | 0.29 | 45,450.52 |
Nivo-ipi | 110,894.43 | 91,388.83 | 1.14 | 0.21 | 435,184.90 |
Atezo-beva-chemo | 140,823.22 | 121,317.62 | 1.36 | 0.43 | 282,134.00 |
Durva-treme-chemo | 112,804.77 | 93,299.17 | 1.05 | 0.12 | 777,493.08 |
Atezo-chemo | 74,841.35 | 55,335.75 | 1.13 | 0.2 | 276,678.75 |
Durva-treme | 73,073.61 | 53,568.01 | 0.91 | -0.02 | - |